FASN inhibition targets multiple drivers of NASH by reducing steatosis, inflammation and fibrosis in preclinical models
Authors:
Open Access
- 19 September 2022
- journal article
- research article
- Published by Springer Nature in Scientific Reports
- Vol. 12 (1) , 1-16
Abstract
Fatty acid synthase (FASN) is an attractive therapeutic target in non-alcoholic steatohepatitis (NASH) because it drives de novo lipogenesis and mediates pro-inflammatory and fibrogenic signaling. We therefore tested pharmacological inhibition of FASN in human cell culture and in three diet induced mouse models of NASH. Three related FASN inhibitors were used; TVB-3664, TVB-3166 and clinical stage TVB-2640 (denifanstat). In human primary liver microtissues, FASN inhibiton (FASNi) decreased triglyceride (TG) content, consistent with direct anti-steatotic activity. In human hepatic stellate cells, FASNi reduced markers of fibrosis including collagen1α (COL1α1) and α-smooth muscle actin (αSMA). In CD4+ T cells exposed to NASH-related cytokines, FASNi decreased production of Th17 cells, and reduced IL-1β release in LPS-stimulated PBMCs. In mice with diet induced NASH l, FASNi prevented development of hepatic steatosis and fibrosis, and reduced circulating IL-1β. In mice with established diet-induced NASH, FASNi reduced NAFLD activity score, fibrosis score, ALT and TG levels. In the CCl4-induced FAT-NASH mouse model, FASN inhibition decreased hepatic fibrosis and fibrosis markers, and development of hepatocellular carcinoma (HCC) tumors by 85%. These results demonstrate that FASN inhibition attenuates inflammatory and fibrotic drivers of NASH by direct inhibition of immune and stellate cells, beyond decreasing fat accumulation in hepatocytes. FASN inhibition therefore provides an opportunity to target three key hallmarks of NASH.Keywords
Funding Information
- Sagimet provided funding for this work.
- NIH Funding (grant number 1 R01 DK128289)
This publication has 48 references indexed in Scilit:
- Inhibition of de novo Palmitate Synthesis by Fatty Acid Synthase Induces Apoptosis in Tumor Cells by Remodeling Cell Membranes, Inhibiting Signaling Pathways, and Reprogramming Gene ExpressionEBioMedicine, 2015
- Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver DiseaseGastroenterology, 2015
- De novo fatty acid synthesis controls the fate between regulatory T and T helper 17 cellsNature Medicine, 2014
- Evaluation of yellow pea fibre supplementation on weight loss and the gut microbiota: a randomized controlled trialBMC Gastroenterology, 2014
- Increased De Novo Lipogenesis Is a Distinct Characteristic of Individuals With Nonalcoholic Fatty Liver DiseaseGastroenterology, 2014
- Role of ceramides in nonalcoholic fatty liver diseaseTrends in Endocrinology & Metabolism, 2012
- Analysis of hepatic genes involved in the metabolism of fatty acids and iron in nonalcoholic fatty liver diseaseHepatology Research, 2009
- A Fluorescence-Based Thiol Quantification Assay for Ultra-High-Throughput Screening for Inhibitors of Coenzyme A ProductionASSAY and Drug Development Technologies, 2008
- Design and validation of a histological scoring system for nonalcoholic fatty liver disease†Hepatology, 2005
- Human hepatic stellate cell lines, LX-1 and LX-2: new tools for analysis of hepatic fibrosisGut, 2004